Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Evidence-based follow-up

Evidence-based follow-up editorial memo (2020) 13:5–6 https://doi.org/10.1007/s12254-019-00568-x Ewald Wöll Received: 17 December 2019 / Accepted: 20 December 2019 © Springer-Verlag GmbH Austria, part of Springer Nature 2020 Although follow-up after primary treatment of cancer Alexander Perathoner [3] sheds light on evidence- patients is our daily business, very few evidence-based based follow-up in colorectal cancer and propagates strategies on the best modalities and time lines have patient-centered surveillance. been published so far. Stefan Watzka [4] illustrates follow-up strategies in Several medical societies however have issued their non-small cell lung cancer emphasizing a more in- recommendations most often based on single insti- tense routine follow-up during the first two years af- tution experience or general common sense rather ter treatment, followed by less frequent regular visits than evidence. Stringent follow-up however could throughout life. lead to early detection of local or systemic relapse and Florian Kocher et al. [5] give a comprehensive possibly lead to better local control or even cure in overview about follow-up strategies in the risk group oligometastatic disease. In a palliative setting, early of recently operated lung cancer patients. They point detection of progress could result in more treatment out that standards differ substantially and that gener- options or http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png memo - Magazine of European Medical Oncology Springer Journals

Evidence-based follow-up

Download PDF
2 pages

Loading next page...
 
/lp/springer-journals/evidence-based-follow-up-Q0eXeJp6gO
Publisher
Springer Journals
Copyright
Copyright © Springer-Verlag GmbH Austria, part of Springer Nature 2020
ISSN
1865-5041
eISSN
1865-5076
DOI
10.1007/s12254-019-00568-x
Publisher site
See Article on Publisher Site

Abstract

editorial memo (2020) 13:5–6 https://doi.org/10.1007/s12254-019-00568-x Ewald Wöll Received: 17 December 2019 / Accepted: 20 December 2019 © Springer-Verlag GmbH Austria, part of Springer Nature 2020 Although follow-up after primary treatment of cancer Alexander Perathoner [3] sheds light on evidence- patients is our daily business, very few evidence-based based follow-up in colorectal cancer and propagates strategies on the best modalities and time lines have patient-centered surveillance. been published so far. Stefan Watzka [4] illustrates follow-up strategies in Several medical societies however have issued their non-small cell lung cancer emphasizing a more in- recommendations most often based on single insti- tense routine follow-up during the first two years af- tution experience or general common sense rather ter treatment, followed by less frequent regular visits than evidence. Stringent follow-up however could throughout life. lead to early detection of local or systemic relapse and Florian Kocher et al. [5] give a comprehensive possibly lead to better local control or even cure in overview about follow-up strategies in the risk group oligometastatic disease. In a palliative setting, early of recently operated lung cancer patients. They point detection of progress could result in more treatment out that standards differ substantially and that gener- options or

Journal

memo - Magazine of European Medical Oncology – Springer Journals

Published: Mar 3, 2020

There are no references for this article.